(Hypertension. 1997;30:1047-1053.)
© 1997 American Heart Association, Inc.
Articles |
Prostacyclin Release by Rat Cardiac Fibroblasts
Inhibition of Collagen Expression
From the Department of Pharmacology, University of California at San Diego, La Jolla.
Correspondence to Morton P. Printz, Department of Pharmacology 0636, University of California at San Diego, Room 3092, Basic Sciences Bldg, La Jolla, CA 92093-0636. E-mail mprintz{at}ucsd.edu
Abstract Cardiac fibroblasts, as the source of extracellular matrix for the left ventricle, subserve important functions to cardiac remodeling and fibrotic development following myocardial infarction or with pressure-overload cardiac hypertrophy. The fibroblast may be the target cell for angiotensin-converting enzyme inhibitors (ACEI) that are cardioprotective and reverse collagen deposition and remodeling but whose mechanisms of action remain controversial. Because we previously documented phenotypic differences between cardiac fibroblasts from the spontaneously hypertensive (SHR) and normotensive Wistar-Kyoto (WKY) left ventricle, the present study evaluated whether phenotypic differences also exist in the release of endogenous arachidonic acid metabolites or in the activation of phospholipase D, and the importance of observed differences to the formation of collagen and the mechanism of action of ACEI. The experimental design compared endogenous sources of arachidonic acid with exogenous prelabeling of cells. Angiotensin II stimulated greater arachidonic acid release than bradykinin, and WKY cells were more responsive than SHR. The major prostanoid formed by cardiac fibroblasts was prostaglandin I2 (PGI2), with more prostacyclin production by WKY cells than SHR cells both under nonstimulated conditions and in response to angiotensin II or bradykinin. Beraprost, a PGI2 analogue, was shown to decrease growth rate and DNA synthesis of fibroblasts and to inhibit mRNA expression for collagen types I and III, with SHR cells being less responsive to beraprost than WKY cells. These results potentially implicate eicosanoid metabolism, particularly PGI2, in collagen formation, fibrotic development, and cardiac remodeling, and they imply that the SHR genetic hypertension model may be predisposed to excess cardiac fibrosis.
Key Words: hypertrophy, left ventricular • collagen types I and III • angiotensin II • arachidonic acid • bradykinin • prostacyclin
This article has been cited by other articles:
 |
|
 |
|
  S. P. Levick, D. C. Loch, S. M. Taylor, and J. S. Janicki Arachidonic Acid Metabolism as a Potential Mediator of Cardiac Fibrosis Associated with Inflammation J. Immunol., January 15, 2007; 178(2): 641 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Lovgren, L. A. Jania, J. M. Hartney, K. K. Parsons, L. P. Audoly, G. A. FitzGerald, S. L. Tilley, and B. H. Koller COX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis Am J Physiol Lung Cell Mol Physiol, August 1, 2006; 291(2): L144 - L156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hara, K.-i. Yuhki, T. Fujino, T. Yamada, K. Takayama, S. Kuriyama, O. Takahata, H. Karibe, Y. Okada, C.-Y. Xiao, et al. Augmented Cardiac Hypertrophy in Response to Pressure Overload in Mice Lacking the Prostaglandin I2 Receptor Circulation, July 5, 2005; 112(1): 84 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Ritchie, A. C. Rosenkranz, L. P. Huynh, T. Stephenson, D. M. Kaye, and G. J. Dusting Activation of IP prostanoid receptors prevents cardiomyocyte hypertrophy via cAMP-dependent signaling Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1179 - H1185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Lopez, R. Querejeta, A. Gonzalez, E. Sanchez, M. Larman, and J. Diez Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure J. Am. Coll. Cardiol., June 2, 2004; 43(11): 2028 - 2035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Ostrom, J. E. Naugle, M. Hase, C. Gregorian, J. S. Swaney, P. A. Insel, L. L. Brunton, and J. G. Meszaros Angiotensin II Enhances Adenylyl Cyclase Signaling via Ca2+/Calmodulin: Gq-Gs CROSS-TALK REGULATES COLLAGEN PRODUCTION IN CARDIAC FIBROBLASTS J. Biol. Chem., June 27, 2003; 278(27): 24461 - 24468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ichihara, T. Senbonmatsu, E. Price Jr, T. Ichiki, F. A. Gaffney, and T. Inagami Targeted Deletion of Angiotensin II Type 2 Receptor Caused Cardiac Rupture After Acute Myocardial Infarction Circulation, October 22, 2002; 106(17): 2244 - 2249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Senbaklavaci, Y. Kaneko, A. Bartunek, C. Brunner, E. Kurkciyan, P. Wunderbaldinger, W. Klepetko, E. Wolner, and W. Mohl Rupture and dissection in pulmonary artery aneurysms: Incidence, cause, and treatment--Review and case report J. Thorac. Cardiovasc. Surg., May 1, 2001; 121(5): 1006 - 1008. [Full Text] [PDF]
|
|
|
|
|
|
N. Iwai, T. Katsuya, K. Ishikawa, T. Mannami, J. Ogata, J. Higaki, T. Ogihara, T. Tanabe, and S. Baba Human Prostacyclin Synthase Gene and Hypertension : The Suita Study Circulation, November 30, 1999; 100(22): 2231 - 2236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C Newby and A. B Zaltsman Fibrous cap formation or destruction -- the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation Cardiovasc Res, February 1, 1999; 41(2): 345 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Gallagher, H. Yu, and M. P. Printz Bradykinin-Induced Reductions in Collagen Gene Expression Involve Prostacyclin Hypertension, July 1, 1998; 32(1): 84 - 88. [Abstract] [Full Text] [PDF]
|
|